ÌÇÐÄÔ­´´

Contact

• workRoom B21 Clinical Sciences Building
  Nottingham City Hospital
  Hucknall Road
  Nottingham
  NG5 1PB
  UK
• Emma.Odowd@nottingham.ac.uk

Biography

Dr Emma O'Dowd is an honorary consultant respiratory physician at Nottingham University Hospitals NHS Trust and associate clinical professor in respiratory medicine at ÌÇÐÄÔ­´´. She was awarded a PhD entitled Factors influencing the diagnosis and subsequent prognosis in patients with lung cancer in April 2017 funded by the Roy Castle Lung Cancer Foundation. Her research interests are lung cancer screening and early diagnosis of lung cancer. She is chair of the British Thoracic Society Lung Cancer & Mesothelioma Advisory Group, member of the Lung Cancer Clinical Expert Group and the IASLC Tobacco Control and Smoking Cessation Committee.

Expertise Summary

Lung cancer screening.

Interventional procedures.

Research Summary

SELECT Selection of Eligible People for Lung Cancer Screening using Electronic Primary Care DaTa: Development of new risk prediction models. £358,737. Cancer Research UK. 2018-2024.… read more

Recent Publications

• O'DOWD, E, BEROVIC, M and CALLISTER, M ET AL, 2024. BMJ Open.
• 2023. Int J Cancer.
• 2023. Thorax.
• 2023. ERJ.

• View all publications

Current Research

1. SELECT Selection of Eligible People for Lung Cancer Screening using Electronic Primary Care DaTa: Development of new risk prediction models. £358,737. Cancer Research UK. 2018-2024. Co-applicant
2. 4-IN-THE-LUNG-RUN Towards INdividually tailored INvitations, screening INtervals, and INtegrated co-morbidity reducing strategies in lung cancer screening): A Randomised Comparison of Personalised Lung Cancer Screening Regimens. €7,999,787. Horizon 20:20. 2020-2024. Co-applicant (€400,000 to Nottingham)
3. DECLINE: DEcisions against Curative treatment for Lung cancer IN Eligible patients. £210,810. Roy Castle Lung Cancer Foundation. 2020-2024. Principal applicant
4. Use of virtual reality to deliver prehabilitation in patients undergoing lung cancer surgery. £144,000. NHSX. 2022-2024. Co-Principal applicant
5. Determining the impact of CT analysis software on lung nodule diagnosis (DOLCE). £1,479,044. NHSX AI. 2022-2025. Co-applicant
6. Phase IV AI. Horizon Europe/ UKRI. Euro 7998990. (Euro 389363 to NUH). Co-applicant. 2023- 2026.

• O'DOWD, E, BEROVIC, M and CALLISTER, M ET AL, 2024. BMJ Open.
• 2023. Int J Cancer.
• 2023. Thorax.
• 2023. ERJ.
• 2023. BMC Cancer.
• 2023. Lancet Public Health.
• 2023. ERJ.
• 2023. Lancet Oncol.
• 2023. Lung Cancer.
• 2023. The British Journal of Radiology.
• 2023. Chest.
• VAN MEERBEECK J, O'DOWD E, WARD B, VAN SCHILL P and SNOECKX A, 2022. Cancers. 14(9), 2343
• MORGAN H, BALDWIN D, HUBBARD R, NAVANI N, WEST D and O'DOWD E, 2022. Thorax.
• BURZIC A, O'DOWD E and BALDWIN D, 2022. Cancer Manag Res.
• BALDWIN D, CALLISTER M, CROSBIE P, O'DOWD E, RINTOUL R, ROBBINS H and STEELE R, 2021. European Respiratory Journal. 57(1),
• ALZUBAIDI A, KAUR J, MAHMUD M, BROWN D, HE J, BALL G, BALDWIN D, O'DOWD E and HUBBARD R, 2021. Applied Intelligence and Informatics.
• MORGAN H, ELLIS L, O'DOWD E, MURRAY R, HUBBARD R and BALDWIN D, 2021. Oncol Ther.
• BALATA H, RUPAREL M, O'DOWD E, LEDSON M, FIELD J, DUFFY S, QUAIFE S, SHARMAN A, JANES S, BALDWIN D, BOOTON R and CROSBIE P, 2021. Lung Cancer. 136-140
• O'DOWD E, TEN HAAF K, KAUR J, DUFFY S, HAMILTON W, HUBBARD R, FIELD J, CALLISTER M, JANES S, DE KONING H, RAWLINSON J and BALDWIN D, 2021. Thorax.
• 2021. Clinical Medicine.
• BALDWIN DR, GUSTAFSON J, PICKUP L, ARTETA C, NOVOTNY P, DECLERCK J, KADIR T, FIGUEIRAS C, STERBA A, EXELL A, POTESIL V, HOLLAND P, SPENCE H, CLUBLEY A, O'DOWD E, CLARK M, ASHFORD-TURNER V, CALLISTER ME and GLEESON FV, 2020. Thorax. 75(4), 306-312
• MORGAN H, O'DOWD E, NAIR A and BALDWIN D, 2020. Translational Lung Cancer Research.
• BALDWIN D, O'DOWD E and TEN HAAF K, 2020. Thorax. 75(8),
• CRISP E, O'DOWD E and BALDWIN D, 2020. Diagnosis and management of malignant pleural mesothelioma Practitioner. 1843
• RUPAREL M, QUAIFE SL, DICKSON JL, HORST C, BURKE S, TAYLOR M, AHMED A, SHAW P, SOO MJ, NAIR A, DEVARAJ A, O'DOWD EL, BHOWMIK A, NAVANI N, SENNETT K, DUFFY SW, BALDWIN DR, SOFAT R, PATEL RS, HINGORANI A and JANES SM, 2019. Thorax. 74(12), 1140-1146
• O'DOWD E and TEN HAAF K, 2019. Thorax.
• MORGAN H, O'DOWD E and BALDWIN D, 2019. Time to diagnosis key in improving lung cancer outcomes Practitioner. 263, 21-25
• HOWARD L, BARDEN S, CONDLIFFE R, CONNOLLY V, DAVIES C, DONALDSON J, EVERETT B, FREE C, HORNER D, HUNTER L, KALER J, NELSON-PIERCY C, O'DOWD E, PATEL R, PRESTON W, SHEARES K and TAIT C, 2018. Thorax.
• HOWARD L, BARDEN S, CONDLIFFE R, CONNOLLY V, DAVIES C, DONALDSON J, EVERETT B, FREE C, HORNER D, HUNTER L, KALER J, NELSON-PIERCY C, O'DOWD E, PATEL R, PRESTON W, SHEARES K and TAIT C, 2018. BMJ Open Resp Res.
• O'DOWD EL and BALDWIN DR, 2017. The British journal of radiology. 20170460
• O'DOWD EL, MCKEEVER TM, BALDWIN DR and HUBBARD RB, 2016. PloS one. 11(8), e0161399
• O'DOWD EL, LÃœCHTENBORG M, BALDWIN DR, MCKEEVER TM, POWELL HA, MØLLER H, JAKOBSEN E and HUBBARD RB, 2016. Lung cancer (Amsterdam, Netherlands). 95, 88-93
• K CUSWORTH, E O'DOWD, R HUBBARD, P BECKETT, M D PEAKE and I WOOLHOUSE, 2015. Thorax.
• E O'DOWD and D BALDWIN, 2015. Br J Hosp Med (Lond). 76(6), C89-93
• E O'DOWD, T MCKEEVER, D BALDWIN, S ANWAR, H POWELL, J GIBSON, B IYEN-OMOFOMAN and R HUBBARD, 2015. Thorax. 70(2), 185
• O'DOWD, E.L., MCKEEVER, T.M., BALDWIN, D.R., ANWAR, S., POWELL, H.A., GIBSON, J.E., IYEN-OMOFOMAN, B. and HUBBARD, R.B., 2015. Thorax. 70(2), 161-168
• E O'DOWD and D BALDWIN, 2014. Early diagnosis pivotal to survival in lung cancer Practitioner. 258(1776), 21-4
• D BALDWIN and E O'DOWD, 2014. Br J Radiol. 87(1044),
• E O'DOWD, M KUMARAN, B PALOMO and D BALDWIN, 2014. Lung Cancer. 86(2), 185-9
• W MCNULTY, E O'DOWD and S KEMP, 2012. Diagnostic and therapeutic flexible bronchoscopy in the management of lung cancer Minerva Pneumologica. 51(2), 59-72